TEVA Teva Pharmaceutical Industries Ltd
- Price as of: Feb 12, 07:42 PM EST
- Drug manufacturers - other
TEVA Stock Dividend DataAdd TEVA to Watchlist
TEVA Upcoming Dividend Payouts
Date has passed
Next Ex-Dividend Date
Next Pay Date
|Amount||Declare Date||Ex-Dividend Date ▲||Record Date||Pay Date||Payout Type|
TEVA Dividend Yield & Stock Price History
TEVA Dividend Payout History
TEVA Daily Snapshot
- Quote Time:
- Feb 12, 07:42 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $53.85 - $56.06
- Previous Close:
- 52 Week Low / High:
- $53.78 - $72.31
- Percent Off 52 Week High:
TEVA Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for TEVA||13.0%||0.8%||3 years|
TEVA Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
TEVA Company Profile
Teva Pharmaceutical Industries Ltd (TEVA) is an Israeli global pharmaceutical company. It develops, produces and markets generic drugs in all treatment categories. Its principal branded pharmaceutical products include Copaxone, Provigil, Nuvigil, Azilect, and Plan B One-Step. Teva is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The firm is based out of Petah Tikva, Israel and was founded in 1901.
Teva Pharmaceutical Industries Ltd News
July 31, 2015
The week started with a bang as global equity markets reacted to Chinese growth and stabilization concerns. In an effort to soften the landing and boost sentiment, Beijing officials confirmed the implementation of a new stock buying program. The...
Teva Pharmaceutical to Cut 5,000 Jobs (TEVA)Oct 10, 2013Teva Pharmaceutical Industries Ltd (TEVA) announced on Thursday that it plans to cut 5,000 jobs in an effort to reduce costs. The pharmaceutical company stated that cutting 5,000 jobs, which accounts for 10% of its workforce, will save the company an estimated $2 billion a year. These cuts are a part of the company's cost-cutting goals, which it hopes to achieve by the end of 2017. Teva estimates that roughly $1 billion will be saved by the end of 2014, and the remaining 70% would come by the end of 2015. This comes after CEO Jeremy Levin vowed in December that the company would reduce annual costs by $1.5 billion to $2 billion over five years. Teva Pharmaceutical shares rallied 3.38% during Thursday's session. Year-to-date, the stock is up 5.40%.Expand to read the full story
Teva Acquires MicroDose Therapeutx (TEVA)Jun 17, 2013Today, Teva Pharmaceuticals (TEVA) announced the purchase of MicroDose Therapeutx for $40M. The Israel-based firm made the move in order to expand its line-up of respiratory products. MicroDose, a private firm, focuses on inhalation technologies to treat lung ailments. Investors should note that as a part of the deal, Teva may pay up to $125 million if certain developmental targets are met. Teva is currently the largest generic drug manufacturer in the world and trades on both the NYSE and the Tel Aviv Stock Exchange. Teva shares were up $0.24 or 0.61% at Monday's close. The stock is currently 8% off of its 52-week highs. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a yield of 2.77% based on Monday's closing price of $39.32. Teva Pharmaceuticals (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Dec 12, 2012These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Lennar Corp...
Jun 25, 2012These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Teva...
May 30, 2012These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Teva...
Teva Pharmaceutical's Numbers Cut at Needham & Co. (TEVA)May 25, 2012Israeli drug maker Teva Pharmaceutical Industries Ltd (TEVA) on Friday caught some tepid commentary from analysts at Needham & Company. The firm maintained its "Hold" rating on TEVA but lowered its 2012 EPS estimate from $5.59 to $5.34, and its 2013 EPS estimate from $6.01 to $5.70. A Needham analyst commented, "A quick two weeks post effectively withdrawing 2012 financial guidance, new Teva management emerged with updated near-term financial objectives that while differing only marginally from prior guidance in the aggregate, clearly set a floor under the 'how bad can it be' thinking that has hung over shares post 1Q12 results. Given current state of sentiment in the name with shares plunging the depths of oversold territory reached on only four occasions in the past decade, a reflex rally is overdue though key structural overhangs, longer-term opacity on evolution of growth initiatives and revamping of strategic priorities, we find little compelling reason to support a significant fundamental outperformance thesis." Teva shares were unchanged in premarket trading Friday. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a 2.77% dividend yield, based on last night's closing stock price of $38.69. The stock has technical support in the $35-$36 price area. If the shares can firm up, we see overhead resistance around the $42 price level. Teva Pharmaceutical Industries Ltd (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.2 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
May 2, 2011These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights International...
Teva Pharmaceuticals to Buy Cephalon for $6.8 Billion in Cash (TEVA)May 2, 2011Israeli drugmaker Teva Pharmaceutical Industries Ltd (TEVA) on Monday announced it would acquire rival pharma company Cephalon (CEPH) for $6.8 billion in cash. The agreed-upon deal marks the end of Valeant Pharmaceuticals' (VRX) hostile bid for Cephalon. Valeant had bid $73, which Cephalon's board rejected as undervaluing the company. Teva will pay $81.50 for CEPH, which marks a 6% upside from the stock's Friday closing price of $77.02. The deal is expected to close in the third quarter. Teva Pharmaceuticals shares rose $1.57, or +3.4%, in premarket trading Monday. The Bottom Line Shares of Teva Pharmaceuticals (TEVA) have a 1.88% dividend yield, based on Friday's closing stock price of $45.73. The stock has technical support in the $40-$42 price area. If the shares can firm up, we see overhead resistance around the $48-$50 price levels. Teva Pharmaceutical Industries Ltd (TEVA) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Dec 9, 2010These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Diamond Foods...